General Practitioners (GPs) in Australia continue to provide primary medical care for patients enrolled in specialist-led clinical trials (CTs), yet research on GPs’ experiences in this role remains limited. This study explored Australian GPs’ experiences managing CT patients and their perspectives on primary care involvement in clinical research.

This phenomenological study involved 11 semi-structured interviews with GPs in New South Wales, Australia, between July to October 2024, who previously managed patients enrolled in other non-GP subspecialist CTs. The recruitment applied purposive, snowballing and convenience sampling approaches. Interviews were transcribed, inductively coded and thematically analyzed.

Analysis revealed four themes: (i) lack of communication from CT teams, (ii) patients’ insufficient understanding about their CTs, (iii) time and resource barriers to GP involvement in CTs, (iv) varied opinions about GPs playing an active role as researchers in CTs.

This exploratory study highlighted the lack of proper communication gaps between CT teams and GPs, potentially compromising the quality of patient care. Digital health records (such as Australia’s My Health Record) could facilitate information sharing. While GPs support primary care research, barriers include limited research training, time constraints, and inadequate resources. Integrating research education into GP training and establishing practice-based research networks could enhance GP participation in CTs.

Having a child with a psychiatric diagnosis is associated with parents’ greater risk of subsequent mental disorders but no immediate change in their annual labour market metrics. This discrepancy could be explained by shorter absences from work. We examined first-time psychiatric sickness absences in parents whose children have psychiatric diagnoses.

Using several linked nationwide Finnish registers, in this cohort study we examined time to first psychiatric sickness absence in parents whose children were born in 2001–2012 (early-childhood-onset diagnoses) or 2005–2016 (late-childhood-onset diagnoses). Exposure was having a child with a psychiatric diagnosis. Follow-up started when the parent’s eldest turned 1 (early-childhood-onset diagnoses) or 5 (late-childhood-onset diagnoses) and ended at psychiatric sickness absence, emigration, 68th birthday, death, or 31 December 2020, whichever occurred first.

The 2001–2012 and 2005–2016 cohorts included 357 135 and 397 874 parents followed for 3.31 and 3.70 million person-years. Having a diagnosed child was associated with greater risk of psychiatric sickness absence in all except men whose children had substance use or psychotic disorder diagnoses. Time-varying analyses showed the greatest associations for women (HR: 4.92; 95% CI: 3.97–6.10) and men (HR: 2.48; 95% CI: 1.61–3.80) within 6 months of a child’s eating disorder diagnosis.

Parents of children with psychiatric diagnoses may be at a greater risk of a psychiatric sickness absence. Associations differed by child’s diagnosis, parent’s gender and time since diagnosis.

Although extensive research has been conducted on the impact of the COVID-19 pandemic on global mental health, a systematic synthesis of the cross-time dynamics of suicidal ideation (SI) remains lacking. This study aims to systematically synthesise the global aggregated prevalence of SI before and after the pandemic, investigate the potential association between pandemic exposure and the SI risk through meta-regression analysis of longitudinal studies, and explore key moderating factors.

A systematic search was conducted in Web of Science, PubMed, PsycINFO and ProQuest databases up to August 2025. Observational studies were included if they employed cross-sectional or longitudinal designs and reported the prevalence of SI before and after the pandemic across global regions.

The analysis included 354 cross-sectional studies (N = 8,247,875) and 27 longitudinal studies. In cross-sectional studies, the pooled prevalence of SI was 13.20% [95% CI 12.06%–14.42%]. Pre-pandemic prevalence was 12.52% [95% CI 8.46%–18.14%], and post-pandemic prevalence was 13.24% [95% CI 12.07%–14.50%], with no significant difference. Meta-regression analysis identified three moderators. Specifically, larger sample sizes (n) were associated with lower prevalence (β = −0.232, P < 0.0001); higher study quality predicted lower prevalence (β = −0.278, P < 0.001); and studies on adults reported significantly lower prevalence than adolescents (β = −0.366, P < 0.05). Conversely, time progression during the pandemic, development level, geographical area, gender and measurement method did not show significant independent effects. Interaction analyses also found no significant moderating effect of economic development level or geographical area on the temporal trend of SI prevalence. Longitudinal analysis found no significant increase in prevalence from the pre-pandemic to the post-pandemic period (P = 0.101). However, a small but significant increase occurred between early and late stages within the pandemic (β = 0.265, P = 0.021). Subgroup analyses showed no significant moderation of these temporal changes.

The COVID-19 pandemic’s impact on SI was dynamic. While no significant prevalence change was found between pre- and post-pandemic periods, a significant increase occurred as the crisis progressed. This deteriorating trend was more pronounced in adolescents, identifying them as a key vulnerable group. Methodologically, findings were moderated by the measurement instrument, study quality and sample size, with evidence suggesting potential small-study effects. These findings underscore the need for robust mental health surveillance and targeted interventions for at-risk populations during prolonged public health crises.

The protocol was registered on PROSPERO (CRD42024603151).

To assess levels of restrictive practice in approved centres in Ireland following the introduction of revised rules and codes of practice and the implementation by the Mental Health Commission (MHC)) as regulator of a near real-time reporting mechanism.

We examined data reported to the MHC via its computerised system from 65 approved centres during a two-year period from 2024 to 2025.

The data indicate an accelerated decline in restrictive practice in approved centres in Ireland.

Restrictive practice (Restraint and Seclusion) has been declining in approved centres in Ireland. This progress accelerated following the implementation of revised, human rights-based Rules governing the use seclusion and a Code of Practice on the use of physical restraint which were developed by the MHC after consultation with stakeholders and came into effect on 1 January 2023. Many factors contributed to this progress including steps taken by the regulator and by approved centres to enhance this welcome trend.

Although the short-term preventive effects of mHealth consultation intervention on postpartum depressive symptoms have been demonstrated, the long-term effects and role of alleviating loneliness on depressive symptoms remain unclear.

This follow-up study extended our previous trial, which ended at three months postpartum, by continuing observation to 12 months. Participants in the original trial were randomized to the mHealth group (n = 365) or the usual care group (n = 369). Women in the mHealth group had access to free, unlimited mHealth consultation services with healthcare professionals from enrollment through four months postpartum. The primary outcome of this study was the risk of elevated postpartum depressive symptoms at 12 months post-delivery (Edinburgh Postnatal Depression Scale score of ≥9). The mediation effect of alleviating loneliness on the primary outcome was also evaluated, using the UCLA loneliness scale at three months postpartum.

A total of 515 women completed the follow-up questionnaires (mHealth group, 253/365; usual care group, 262/369; 70.2% of the original participants). Compared to the usual care group, the mHealth group had a lower risk of elevated postpartum depressive symptoms at 12 months post-delivery (36/253 [14.2%] vs. 55/262 [21.0%], risk ratio: 0.68 [95% confidence interval: 0.46–0.99]). Mediation analysis showed that reducing loneliness at three months post-delivery mediated approximately 20% of the total effect of the intervention on depressive symptoms 12 months post-delivery.

mHealth consultation services provided during the early perinatal period may help alleviate depressive symptoms at 12 months postpartum.

Long COVID remains poorly characterized at the genomic level. The primary aim of this study was to examine the relationship between viral sequences and the incidence of Long COVID at a tertiary care center in Louisiana between April 2020 and December 2022. A secondary aim was analysis of the Spike protein to identify conserved regions for multivalent vaccine targets.

To estimate Long COVID incidence across variants, we linked 4789 SARS-CoV-2 sequences to 3090 de-identified patient electronic health record information. The base population was defined as any patient with an International Classification of Diseases-10-Clinical Modification COVID-19 diagnosis code (U07.1) based definitions of Long COVID presentation developed by the N3C consortium.

1,554 patients (1,536 Long COVID-negative) met Long COVID definitions, with 56.3% being female, 36.1% self-reported as African American, 5.5% self-reported as Hispanic/Latino, and 54.5% had received at least one vaccine dose 14 days prior to SARS-CoV-2 collection. Long COVID-positive patients were older (mean age 43.1 years) than negative patients (35.9 years; p = 0.0054) and were more likely to be female (p = 0.0001). Among unvaccinated patients, those with Long COVID were significantly younger than their vaccinated counterparts (p < 0.00001). Long COVID incidence varied by PANGO lineage, ranging between 14% in AY.13 to 67.8% in B.1.1.7. Analysis of spike protein diversity revealed eight conserved amino acid regions (Shannon entropy < 0.43), representing potential targets for vaccine design.

Long COVID rates across thousands of annotated SARS-CoV-2 sequences revealed lineage-specific risk and conserved epitopes for future interventions.